Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

BACKGROUND AND OBJECTIVE: The TOWER and INO-VATE-ALL trials demonstrated the efficacy and safety of blinatumomab and inotuzumab ozogamicin (inotuzumab), respectively, versus standard-of-care (SOC) chemotherapy in adults with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Delea, Thomas E., Zhang, Xinke, Amdahl, Jordan, Boyko, Diana, Dirnberger, Franziska, Campioni, Marco, Cong, Ze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830399/
https://www.ncbi.nlm.nih.gov/pubmed/31218655
http://dx.doi.org/10.1007/s40273-019-00812-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830399/
https://www.ncbi.nlm.nih.gov/pubmed/31218655
http://dx.doi.org/10.1007/s40273-019-00812-6

Ejemplares similares